Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Key Highlights
- ➤Medicus CEO to present targeted cancer therapeutics at two biotechnology conferences
- ➤CD228V prioritizes clinical proof-of-concept in relapsed, refractory melanoma
- ➤FDA authorized initiation of SKNJCT-005 registrational Phase 2b study
- ➤SkinJect targets basal cell carcinoma lesions in Gorlin syndrome patients
- ➤CD228V and SkinJect remain investigational; safety and efficacy unestablished
Expert Statements
Raza Bokhari, Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd.
“Precision Medicine: From Capital to Success”
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer, will present at BioFuture 2026 in New York City and deliver a keynote at Global Biotechnology Summit 2026 in Abu Dhabi.
The presentations will highlight the Company's progress around targeted cancer therapeutics, anchored by CD228V, an investigational antibody-drug conjugate (ADC) molecule utilizing an established vedotin linker-payload platform, as well as SkinJect®, an investigational localized immuno-oncology precision product, for multiple basal cell carcinoma lesions in patients with Gorlin syndrome, a rare autosomal dominant genetic disease.
Get started
Create a free account to read the full story.